Acute Myeloid Leukemia
The latest news, research, and perspectives in acute myeloid leukemia (AML). AML, an aggressive blood cancer, is the most common type of acute leukemia in adults and most often develops when myeloid cells that normally develop into the various types of mature blood cells instead form abnormal myeloblasts.
Advertisement
The 60-day mortality rate was around twice as high in patients with KMT2A rearrangement.
While NPM1 mutations impacted CR rates, they had “no impact” on RFS and OS after each line of salvage therapy.
Revumenib is a potent, selective oral inhibitor of interaction between menin and KMT2A.
A new study suggests CR with MRD negativity should be the “key objective" of high- and low-intensity therapy for AML.
The FDA has approved an Investigational New Drug application for EP0042, a dual FLT-3 and aurora kinase inhibitor.
A multivariate analysis identified 11 "consistent independent adverse factors" associated with survival.
Advertisement
The Clever-1 targeting antibody is currently under evaluation in clinical trials as part of a combination therapy.
Mitochondrial targeting strategies could be combined with chemotherapy as part of induction and consolidation for AML.
Advocates hope it will bring much-needed changes to patient care for complex cancers—including hematologic malignancies.
Data from a recent preclinical study “support combining ERK1/2 and BCL-2 inhibitors” in the treatment of AML.
The optical genome mapping platform will have clinical implications for patients with acute myeloid leukemia and MDS.
These results have potential implications for the long-term success of venetoclax therapy.
The study also found DDX41 germline variants explained approximately 80% of known germline predisposition to MNs in adults.
Combining proteomic data with genetic risk-stratification data may help tailor therapy for pediatric AML.
Maintenance therapy strategies for AML have been investigated for decades, including single agents and combinations.
A participant’s death led to a voluntary pause of a phase I/II trial evaluating MGTA-117 in relapsed/refractory AML and ...
The U.S. Food and Drug Administration has granted Orphan Drug Designation for JBI-802 for the treatment of AML.
A phase III trial of enasidenib in patients with IDH2-mutated AML failed to meet its primary endpoint.
Vemurafenib retreatment may be a “safe and effective option” for patients with relapsed/refractory hairy cell leukemia.
Venetoclax plus gilteritinib is a “potentially active regimen” in patients with high-risk wild-type FLT3 AML.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
670 Madison Ave.
Manalapan, NJ 07726